Table 1.

Summary of demographic and clinical characteristics.

Group	Case	Clinical phenotype	Age (years)	Age of onset (years)	Gender	Education (years)	CDR	MoCA	WAB-R AQ
MSI−	1	lvPPA	71	65–69	F	14	0.5	21	86.2
	2	lvPPA	68	65–69	F	12	0	23	83
	3	lvPPA	73	60–64	M	16	0.5	15	81.1
	4	lvPPA	71	65–69	M	16	0.5	19	81.4
	5	lvPPA	69	60–64	M	16	0.5	13	75.2
	6	lvPPA	72	65–69	M	12	—	12	78.1
	7	lvPPA	56	50–54	F	16	1	14	69.8
	8	lvPPA	71	60–64	F	16	0.5	20	75
	9	lvPPA	77	70–74	M	12	1	—	61.2
MSI+	10	PPAOS	70	65–69	M	19	0.5	26	96.6
	11	nfvPPA	70	65–69	F	14	0.5	22	81.2
	12	CBS	51	45–49	F	14	0.5	25	86.4
	13	PSP	61	55–59	F	14	0.5	22	93.8
	14	nfvPPA	76	70–74	F	16	0	25	89.1
	15	PSP	70	65–69	M	16	1	16	86.4
	16	PPAOS	74	70–74	M	20	0	28	96.6
	17	PPAOS	73	70–74	F	16	0	28	94.5
	18	PPAOS	65	60–64	F	15	0.5	27	96.4
	19	CBS	76	65–69	F	14	0.5	27	81.8
	20	nfvPPA	72	65–69	F	18	0.5	6	54.4

Note. Em dashes indicate data not available. CDR is scored on a common interval scale: 0 = no impairment, 0.5 = very mild impairment, 1 = mild impairment, 2 = moderate impairment, and 3 = severe impairment. CDR = (global) clinical dementia rating; MoCA = Montreal Cognitive Assessment (score range: 0 [worst] to 30 [best]); WAB-R AQ = Western Aphasia Battery–Revised Aphasia Quotient (a weighted summary score indicating overall aphasia severity, score range: 0 [severe aphasia] to 100 [no aphasia]); MSI− = non–motor-speech-impaired group of individuals with logopenic variant primary progressive aphasia; lvPPA = logopenic variant primary progressive aphasia; MSI+ = motor-speech–impaired group of individuals with nfvPPA, PPAOS, CBS, or PSP and suspected four-repeat tauopathy pathology; F = female; M = male; PPAOS = primary progressive apraxia of speech; nfvPPA = nonfluent variant primary progressive aphasia; CBS = corticobasal syndrome; PSP = progressive supranuclear palsy.